Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared.
Hietanen
P
P
Department of Radiotherapy and Oncology, University Central Hospital of Helsinki, Finland.
Blomqvist
C
C
Wasenius
V M
VM
Niskanen
E
E
Franssila
K
K
Nordling
S
S
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004273:DNA, Neoplasm / Q000235:genetics*; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D011003:Ploidies; D011237:Predictive Value of Tests; D016196:S Phase / Q000502:physiology*; D012983:Soft Tissue Neoplasms / Q000556:secondary
D004273:DNA, Neoplasm; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil